Fay Zhou and Arthur Peng of Linklaters review major developments in China's anti-trust regulations that aim to offer clearer guidance and more efficient enforcement actions that can impact on this area of law for the next decade. These developments include stronger deterrence, expanded substantive prohibitions, public interest litigation and a firmer stance against consolidation.
With the entrenchment of reciprocal US-China sanctions and export controls in the past year, counsel have helped clients enact fundamental changes to their approach to making deals, from contractual terms to due diligence
Kevin Yuan, Lucca Li and Jocelyn Chen of FenXun Partners discuss China's efforts to support continuous financial innovation in 2021 based on steady development including taking steps to protect the security of personal data in the midst of rapid developments in finance and technology, implementing detailed rules and new initiatives related to fintech innovation, and taking clear steps to open up the financial market to the outside world.
Chinese IPOs in the United States have slowed for several years now, but a raft of regulatory developments in the past year mainly driven by cybersecurity and national security concerns have likely rung the closing bell
VIE overseas listings require government consent
Foreign investors are allowed to conduct social surveys
Charles Wu and Zaiguang Lu of Han Kun Law Offices review the significant legislative developments of 2021 affecting China's private equity and venture capital industry, and offer insights on the key trends, challenges and opportunities in the sector
Groundbreaking algorithm recommendation regulation finalized; CSRC pilots market makers for STAR Market; and copyright administration prohibits digital music exclusive copyright arrangements
Live streamers may bear advertising liability
Ting Wu of Haiwen & Partners reviews the regulatory reforms taking place in China's life science and healthcare sector including legislation that has been released to encourage innovation and broaden market access to drugs, implementation of the patent linkage system, increasing antitrust enforcement pressure in the pharma sector, regulating medical devices, cosmetics and online hospitals.
